Skip to main content
Erschienen in: Der Ophthalmologe 12/2012

01.12.2012 | Leitthema

Aktuelle Therapieoptionen bei Frühgeborenenretinopathie

verfasst von: PD Dr. T.U. Krohne, S. Aisenbrey, F.G. Holz

Erschienen in: Die Ophthalmologie | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Frühgeborenenretinopathie ist eine der wenigen potenziell zur Erblindung führenden Netzhauterkrankungen des Kindesalters, bei der eine Verhinderung des Sehverlusts durch adäquate und rechtzeitige Therapie möglich ist. Netzhautablative Verfahren wie die Laserkoagulation können die krankheitsursächliche „Vascular endothelial growth factor“ (VEGF)-Sekretion der avaskulären peripheren Netzhaut unterbinden. Eine Blockade der VEGF-Aktivität durch intravitreale Applikation VEGF-hemmender Medikamente hat sich in aktuellen klinischen Studien ebenfalls als wirksam erwiesen. Fortgeschrittene Erkrankungsstadien können den Einsatz chirurgischer Verfahren erforderlich machen. Kenntnisse der Indikationen und Techniken der verschiedenen aktuell zur Verfügung stehenden Therapieverfahren sind entscheidend für die optimale Versorgung der betroffenen Kinder.
Literatur
1.
Zurück zum Zitat Arevalo JF, Maia M, Flynn HW Jr et al (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213–216PubMedCrossRef Arevalo JF, Maia M, Flynn HW Jr et al (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213–216PubMedCrossRef
2.
Zurück zum Zitat Autrata R, Krejcirova I, Senkova K et al (2012) Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol 22(5):687–694PubMed Autrata R, Krejcirova I, Senkova K et al (2012) Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol 22(5):687–694PubMed
3.
Zurück zum Zitat Averbukh E (2005) The evidence supporting the early treatment for type 1 retinopathy of prematurity needs further evaluation. Arch Ophthalmol 123:406 (discussion 409–410)PubMedCrossRef Averbukh E (2005) The evidence supporting the early treatment for type 1 retinopathy of prematurity needs further evaluation. Arch Ophthalmol 123:406 (discussion 409–410)PubMedCrossRef
4.
Zurück zum Zitat Banach MJ, Ferrone PJ, Trese MT (2000) A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity. Ophthalmology 107:324–327 (discussion 328)PubMedCrossRef Banach MJ, Ferrone PJ, Trese MT (2000) A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity. Ophthalmology 107:324–327 (discussion 328)PubMedCrossRef
5.
Zurück zum Zitat Carneiro AM, Costa R, Falcao MS et al (2012) Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 90:e25–e30PubMedCrossRef Carneiro AM, Costa R, Falcao MS et al (2012) Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 90:e25–e30PubMedCrossRef
6.
Zurück zum Zitat Choi J, Kim JH, Kim SJ et al (2011) Long-term results of lens-sparing vitrectomy for stages 4B and 5 retinopathy of prematurity. Korean J Ophthalmol 25:305–310PubMedCrossRef Choi J, Kim JH, Kim SJ et al (2011) Long-term results of lens-sparing vitrectomy for stages 4B and 5 retinopathy of prematurity. Korean J Ophthalmol 25:305–310PubMedCrossRef
7.
Zurück zum Zitat Compernolle V, Brusselmans K, Acker T et al (2002) Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 8:702–710PubMed Compernolle V, Brusselmans K, Acker T et al (2002) Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 8:702–710PubMed
8.
Zurück zum Zitat Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988) Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 106:471–479CrossRef Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988) Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 106:471–479CrossRef
9.
Zurück zum Zitat Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft, Berufsverband der Augenärzte Deutschlands (2012) Stellungnahme zum Einsatz von Bevacizumab in der Therapie der Frühgeborenenretinopathie. Ophthalmologe 109:197–204 Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft, Berufsverband der Augenärzte Deutschlands (2012) Stellungnahme zum Einsatz von Bevacizumab in der Therapie der Frühgeborenenretinopathie. Ophthalmologe 109:197–204
10.
Zurück zum Zitat Early Treatment For Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684–1694CrossRef Early Treatment For Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684–1694CrossRef
11.
12.
Zurück zum Zitat European MAE (2007) Lucentis: scientific discussion (March 14, 2007). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000715/WC500043550.pdf (Zugegriffen: 21.10.2011) European MAE (2007) Lucentis: scientific discussion (March 14, 2007). http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​EPAR_​-_​Scientific_​Discussion/​human/​000715/​WC500043550.​pdf (Zugegriffen: 21.10.2011)
13.
Zurück zum Zitat Hairston RJ, Maguire AM, Vitale S et al (1997) Morphometric analysis of pars plana development in humans. Retina 17:135–138PubMedCrossRef Hairston RJ, Maguire AM, Vitale S et al (1997) Morphometric analysis of pars plana development in humans. Retina 17:135–138PubMedCrossRef
14.
Zurück zum Zitat Hardy RJ, Good WV, Dobson V et al (2004) Multicenter trial of early treatment for retinopathy of prematurity: study design. Control Clin Trials 25:311–325PubMedCrossRef Hardy RJ, Good WV, Dobson V et al (2004) Multicenter trial of early treatment for retinopathy of prematurity: study design. Control Clin Trials 25:311–325PubMedCrossRef
15.
Zurück zum Zitat Hartnett ME, Maguluri S, Thompson HW et al (2004) Comparison of retinal outcomes after scleral buckle or lens-sparing vitrectomy for stage 4 retinopathy of prematurity. Retina 24:753–757PubMedCrossRef Hartnett ME, Maguluri S, Thompson HW et al (2004) Comparison of retinal outcomes after scleral buckle or lens-sparing vitrectomy for stage 4 retinopathy of prematurity. Retina 24:753–757PubMedCrossRef
16.
Zurück zum Zitat Hashimoto T, Zhang XM, Chen BY et al (2006) VEGF activates divergent intracellular signaling components to regulate retinal progenitor cell proliferation and neuronal differentiation. Development 133:2201–2210PubMedCrossRef Hashimoto T, Zhang XM, Chen BY et al (2006) VEGF activates divergent intracellular signaling components to regulate retinal progenitor cell proliferation and neuronal differentiation. Development 133:2201–2210PubMedCrossRef
17.
Zurück zum Zitat Hinz BJ, Juan E de Jr, Repka MX (1998) Scleral buckling surgery for active stage 4A retinopathy of prematurity. Ophthalmology 105:1827–1830PubMedCrossRef Hinz BJ, Juan E de Jr, Repka MX (1998) Scleral buckling surgery for active stage 4A retinopathy of prematurity. Ophthalmology 105:1827–1830PubMedCrossRef
18.
Zurück zum Zitat Hoerster R, Muether P, Dahlke C et al (2012) Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol [Epub ahead of print] Hoerster R, Muether P, Dahlke C et al (2012) Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol [Epub ahead of print]
19.
Zurück zum Zitat Hu J, Blair MP, Shapiro MJ et al (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130:1000–1006PubMedCrossRef Hu J, Blair MP, Shapiro MJ et al (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130:1000–1006PubMedCrossRef
20.
Zurück zum Zitat International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991–999CrossRef International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123:991–999CrossRef
21.
Zurück zum Zitat Jandeck C, Kellner U, Lorenz B et al (2008) Guidelines for ophthalmologic screening of premature infants. Ophthalmologe 105:955–963PubMedCrossRef Jandeck C, Kellner U, Lorenz B et al (2008) Guidelines for ophthalmologic screening of premature infants. Ophthalmologe 105:955–963PubMedCrossRef
22.
Zurück zum Zitat Krohne TU, Eter N, Holz FG et al (2008) Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146:508–512PubMedCrossRef Krohne TU, Eter N, Holz FG et al (2008) Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 146:508–512PubMedCrossRef
23.
Zurück zum Zitat Krohne TU, Liu Z, Holz FG et al (2012) Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 154:682–686PubMedCrossRef Krohne TU, Liu Z, Holz FG et al (2012) Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 154:682–686PubMedCrossRef
24.
Zurück zum Zitat Laws DE, Haslett R, Ashby D et al (1994) Axial length biometry in infants with retinopathy of prematurity. Eye (Lond) 8(Pt 4):427–430 Laws DE, Haslett R, Ashby D et al (1994) Axial length biometry in infants with retinopathy of prematurity. Eye (Lond) 8(Pt 4):427–430
25.
Zurück zum Zitat Lorenz B (2011) Kommentar: Anti-VEGF-Einsatz gut abwägen. Klin Monatsbl Augenheilkd 225:488–490 Lorenz B (2011) Kommentar: Anti-VEGF-Einsatz gut abwägen. Klin Monatsbl Augenheilkd 225:488–490
26.
Zurück zum Zitat Lorenz B, Spasovska K, Elflein H et al (2009) Wide-field digital imaging based telemedicine for screening for acute retinopathy of prematurity (ROP). Six-year results of a multicentre field study. Graefes Arch Clin Exp Ophthalmol 247:1251–1262PubMedCrossRef Lorenz B, Spasovska K, Elflein H et al (2009) Wide-field digital imaging based telemedicine for screening for acute retinopathy of prematurity (ROP). Six-year results of a multicentre field study. Graefes Arch Clin Exp Ophthalmol 247:1251–1262PubMedCrossRef
27.
Zurück zum Zitat Lu JF, Bruno R, Eppler S et al (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779–786PubMedCrossRef Lu JF, Bruno R, Eppler S et al (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779–786PubMedCrossRef
28.
Zurück zum Zitat Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398PubMedCrossRef Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398PubMedCrossRef
29.
Zurück zum Zitat Matsuyama K, Ogata N, Matsuoka M et al (2010) Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 94:1215–1218PubMedCrossRef Matsuyama K, Ogata N, Matsuoka M et al (2010) Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 94:1215–1218PubMedCrossRef
30.
Zurück zum Zitat Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603–615PubMedCrossRef Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603–615PubMedCrossRef
31.
Zurück zum Zitat Moshfeghi DM, Berrocal AM (2011) Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmology 118:1227–1228PubMed Moshfeghi DM, Berrocal AM (2011) Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmology 118:1227–1228PubMed
32.
Zurück zum Zitat Muether PS, Kribs A, Hahn M et al (2012) No advanced retinopathy of prematurity stages 4 or 5 in a large high-risk German cohort. Br J Ophthalmol 96:400–404PubMedCrossRef Muether PS, Kribs A, Hahn M et al (2012) No advanced retinopathy of prematurity stages 4 or 5 in a large high-risk German cohort. Br J Ophthalmol 96:400–404PubMedCrossRef
33.
Zurück zum Zitat Ng EY, Connolly BP, McNamara JA et al (2002) A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. Ophthalmology 109:928–934 (discussion 935)PubMedCrossRef Ng EY, Connolly BP, McNamara JA et al (2002) A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. Ophthalmology 109:928–934 (discussion 935)PubMedCrossRef
34.
Zurück zum Zitat Palmer EA, Hardy RJ, Dobson V et al (2005) 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 123:311–318PubMedCrossRef Palmer EA, Hardy RJ, Dobson V et al (2005) 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 123:311–318PubMedCrossRef
35.
Zurück zum Zitat Patel CK, Walker NJ, Kam JK (2010) A new, theoretically safer method of intravitreal injection of bevacizumab in progressive retinopathy of prematurity using scleral trans-illumination. Br J Ophthalmol 94:1107–1109PubMedCrossRef Patel CK, Walker NJ, Kam JK (2010) A new, theoretically safer method of intravitreal injection of bevacizumab in progressive retinopathy of prematurity using scleral trans-illumination. Br J Ophthalmol 94:1107–1109PubMedCrossRef
36.
Zurück zum Zitat Prenner JL, Capone A Jr, Trese MT (2004) Visual outcomes after lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Ophthalmology 111:2271–2273PubMedCrossRef Prenner JL, Capone A Jr, Trese MT (2004) Visual outcomes after lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Ophthalmology 111:2271–2273PubMedCrossRef
37.
Zurück zum Zitat Sato T, Wada K, Arahori H et al (2012) Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153:327–333PubMedCrossRef Sato T, Wada K, Arahori H et al (2012) Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153:327–333PubMedCrossRef
38.
Zurück zum Zitat Sears JE, Sonnie C (2007) Anatomic success of lens-sparing vitrectomy with and without scleral buckle for stage 4 retinopathy of prematurity. Am J Ophthalmol 143:810–813PubMedCrossRef Sears JE, Sonnie C (2007) Anatomic success of lens-sparing vitrectomy with and without scleral buckle for stage 4 retinopathy of prematurity. Am J Ophthalmol 143:810–813PubMedCrossRef
39.
Zurück zum Zitat Section on Ophthalmology American Academy of Pediatrics, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus (2006) Screening examination of premature infants for retinopathy of prematurity. Pediatrics 117:572–576CrossRef Section on Ophthalmology American Academy of Pediatrics, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus (2006) Screening examination of premature infants for retinopathy of prematurity. Pediatrics 117:572–576CrossRef
40.
Zurück zum Zitat Seiberth V, Linderkamp O, Vardarli I (1997) Transscleral vs transpupillary diode laser photocoagulation for the treatment of threshold retinopathy of prematurity. Arch Ophthalmol 115:1270–1275PubMedCrossRef Seiberth V, Linderkamp O, Vardarli I (1997) Transscleral vs transpupillary diode laser photocoagulation for the treatment of threshold retinopathy of prematurity. Arch Ophthalmol 115:1270–1275PubMedCrossRef
41.
Zurück zum Zitat Wilkinson AR, Haines L, Head K et al (2009) UK retinopathy of prematurity guideline. Eye (Lond) 23:2137–2139 Wilkinson AR, Haines L, Head K et al (2009) UK retinopathy of prematurity guideline. Eye (Lond) 23:2137–2139
42.
Zurück zum Zitat Zepeda-Romero LC, Liera-Garcia JA, Gutierrez-Padilla JA et al (2010) Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity. Eye (Lond) 24:931–933 Zepeda-Romero LC, Liera-Garcia JA, Gutierrez-Padilla JA et al (2010) Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity. Eye (Lond) 24:931–933
Metadaten
Titel
Aktuelle Therapieoptionen bei Frühgeborenenretinopathie
verfasst von
PD Dr. T.U. Krohne
S. Aisenbrey
F.G. Holz
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
Die Ophthalmologie / Ausgabe 12/2012
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI
https://doi.org/10.1007/s00347-012-2618-8

Weitere Artikel der Ausgabe 12/2012

Der Ophthalmologe 12/2012 Zur Ausgabe

Einführung zum Thema

Frühgeborenenretinopathie

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.